Viewing nowHyundai Pregabalin Capsule 75 mg
Pregabalin 75mg
Hard capsule · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

MFDS item code 201109140 · Approved 2011.10.25 · Insurance code 642003000
Treatment of neuropathic pain, adjunctive treatment of partial-onset seizures, treatment of fibromyalgia
This medication is used to treat peripheral and central neuropathic pain in adults. It is also administered as an adjunct for partial seizures in epilepsy patients, effective regardless of the presence of secondary systemic symptoms. Additionally, it is used to alleviate symptoms of fibromyalgia. It helps various neurological-related conditions, improving the quality of life for patients.
Administer the total daily dose of this medicine, as pregabalin, orally in 2 divided doses, regardless of food. This medicine is primarily excreted by the kidneys; therefore, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with renal impairment’.) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional week, the dose may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of treatment’.) 2. Epilepsy Adults: This medicine may be administered at an initial dose of 150 mg/day. Based on each patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, the dose may then be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medicine for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day); based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of treatment Based on current clinical experience, if treatment with this medicine is discontinued, it should be withdrawn gradually over a period of at least 1 week. 5. Patients with renal impairment Since the clearance of this medicine is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. This medicine is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered promptly after each 4-hour hemodialysis session. [Table 1]. Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) / Initial dose (mg/day) / Maximum dose (mg/day) / Dosing regimen ≥60 / 150 / 600 / BID or TID ≥30 -<60 / 75 / 300 / BID or TID ≥15 -<30 / 25-50 / 150 / QD or BID <15 / 25 / 75 / QD Supplemental dose after hemodialysis / 25 / 100 / Single dose b TID = Total daily dose divided into 3 doses BID = Total daily dose divided into 2 doses QD = Once daily a: The total daily dose (mg/day) should be divided as specified by the dosing regimen. b: A supplemental dose refers to an additional dose given once. 6. Patients with hepatic impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years of age: Use is not recommended because there are insufficient safety and efficacy data. Adolescent patients aged 12 to 17 years: Use is not recommended because there are insufficient safety and efficacy data.
This medication may increase the risk of suicidal thoughts or behaviors; therefore, if symptoms of depression or mood changes occur during treatment, it is important to inform the healthcare provider immediately. Those with allergies to any ingredients in this medication or with certain genetic lactose intolerance disorders should not take it. Diabetic patients should be cautious as weight gain may affect blood sugar control, and if signs of angioedema occur, such as swelling of the face or mouth, treatment should be discontinued immediately. Elderly individuals may be at risk of falling due to dizziness or drowsiness associated with this medication, and caution is necessary due to possible changes in vision. If this medication is stopped suddenly, withdrawal symptoms such as insomnia, headache, and anxiety may occur, so dosage should be gradually reduced in consultation with a healthcare provider. Taking this medication with other substances affecting the central nervous system could lead to severe side effects such as respiratory depression, so the healthcare provider must be informed of any concurrent medication. In early pregnancy, it could affect the fetus, so women who are pregnant or planning to become pregnant should consult a healthcare provider before starting treatment and use effective contraceptive methods. This medication can cause dizziness and drowsiness, so caution is needed when driving or operating dangerous machinery. In the event of overdose, severe drowsiness, confusion, seizures, etc., may occur, requiring immediate emergency treatment. Keep out of the reach of children, and do not transfer to another container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air and moisture, so it should be stored in a sealed container. It is important to maintain the storage temperature between 15°C and 30°C to preserve the drug's effectiveness and safety over time.
A hard capsule with an upper reddish-brown and lower white part containing white powder that is white or light yellow.
30 capsules/bottle, 60 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowPregabalin 75mg
Hard capsule · Prescription medication
Hyundai Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.